Cancer pain further incorporates a range of aetiological factors, with about 75% of pain caused by the cancer itself, and the remainder caused by diagnostic procedures and treatments. Tumours cause pain by compressing or invading healthy innervated tissue, triggering inflammation or infection, or releasing chemicals that make normally non-painful stimuli painful. Accordingly, cancer pain is often classified as somatic, visceral or neuropathic in origin. In advanced cancer, multiple mechanisms of pain often occur simultaneously at different sites. Each mechanism and anatomical site requires focused investigation. For example, a patient with advanced cancer may experience liver capsule pain from liver metastases, back pain from spinal metastases and neuropathic pain from systemic chemotherapy regimens. Management of such pain may require corticosteroids, radiotherapy and anti-epileptics for the liver, bone and neuropathic pain, respectively. In such a case, pain would be inadequately managed if each source of pain was not carefully considered and assessed.

Not all cancer patients will experience all modalities of cancer pain, but for optimal cancer pain assessment and control all potential modalities of pain must be considered for each patient and addressed appropriately.

**HOW DO WE CURRENTLY ASSESS PAIN IN CANCER PATIENTS?**

As with all pain syndromes, accurate, thorough, and systematic assessment of cancer pain is crucial to identifying the underlying aetiology and developing a treatment plan.
and improved documentation of pain assessment. A variety of assessment tools have reduced variability in pain reporting. These methods leading to inaccurate monitoring of pain and pain control. As such, the development of standardised assessment tools have reduced variability in pain reporting and improved documentation of pain assessment. A variety of tools have been designed to assess pain in cancer.

Pain intensity scales are unidimensional and include the 11-point numeric rating scale, a verbal descriptor scale (mild, moderate or severe) or a visual analogue scale (a line of increased severity). There are also scales that use drawings of faces to facilitate patients who cannot easily use the above tools. These are very useful for confirming the presence of pain, gaining some basic information about that pain, tracking the course of pain over time and determining the efficacy of pain management. Multidimensional tools, including the Brief Pain Inventory and the McGill Pain Questionnaire, are clinically useful in cancer patients as they assess not only the location and severity of pain but evaluate impairment due to pain. The use of multidimensional scales including the Edmonton Symptom Assessment Scale and the Distress Thermometer that include the most common symptoms (e.g. depression, pain, fatigue) may help in identifying symptom clusters and may also assess psychological, practical and spiritual aspects to pain in a systematic manner.

Such scales used together can assist doctors and other caregivers to standardise pain assessment and to monitor pain appropriately and objectively. They also facilitate the development of guidelines for pain management on the ward that can be utilised by less experienced staff.

IDENTIFYING AND OVERCOMING CHALLENGES OF CANCER PAIN ASSESSMENT

Despite cancer pain being widely treatable, it is often undermanaged due to poor pain assessment. The barriers to effective assessment and management can be broadly characterised by factors relating to the patient, healthcare professional and healthcare system.

PATIENT FACTORS: OPTIMISING COMMUNICATION

The assessment of pain relies heavily on patient reporting. The most significant patient-related barriers are the patient’s reluctance to report pain and adhere to treatment recommendations. Patients may, in some instances, under-report pain for a variety of reasons including the belief that cancer pain is inevitable and should be tolerated, that reporting pain may distract from treatment of the primary disease and fears that pain may indicate progression of disease. Cancer and pain are not synonymous, and not all cancer patients experience pain. Addressing fears and false beliefs is the responsibility of the attending physician and should be performed early in the diagnosis. Patients should also be fully educated about different presentations of pain, their meaning and the efficacy of available treatment options. Patients may also harbour fears regarding the analgesics themselves and their efficacy. Many patients fear that early pain control will promote tolerance and impede control later in the disease. Patients are also often hesitant to take opioid analgesia because of stigma and concerns with dependence. Concerns about side effects can further prevent cancer patients from reporting pain and seeking appropriate care. These issues must be borne in mind by doctors and other healthcare providers when treating all cancer patients and relevant information giving should be provided to patients upon diagnosis to allay fears and false beliefs.

Pain is considered a ‘mind-body’ experience with the ‘mind’ encompassing the perception and interpretation of pain while the ‘body’ encompasses the pathways and processing of pain. It is for this reason that self-reporting is central to the assessment of pain. In non-communicative patients, the mind-body experience cannot be articulated through self-reporting. Non-verbal cancer patients can include those at the extremes of age, comatose or unconscious patients, the critically ill and the cognitively impaired. The International Association for the Study of Pain (IASP) states, “The inability to communicate verbally does not negate the possibility that an individual is experiencing pain and is in need of appropriate pain-relieving treatment”. Clinicians must therefore tailor pain assessment to non-verbal patients and this has been a significant challenge in the field. Current evidence indicates that the best predictors of pain in non-verbal patients are physiological parameters, including blood pressure and pulse rate, and behavioural indicators. Physiological measures are, however, indicators only and are not sensitive screening tools. As such, tools like the Behavioural Pain Scale and Checklist of Non-Verbal Pain Indicators (CNPI) have been developed to assess pain by scoring observable behaviours including facial expressions, movement of upper limbs and vocalisation. As with verbal patients, pre-emptive pain assessment using a valid tool and timely intervention can accurately identify pain and facilitate its management.

HEALTHCARE PROFESSIONAL FACTORS: IMPROVING KNOWLEDGE, SKILLS AND ATTITUDES

Poor assessment of pain and inadequate knowledge on the part of clinicians have been identified as major barriers to cancer pain treatment. Medical graduates will ultimately undertake the task of identifying, assessing and treating patients with cancer pain. Thus, the IASP has emphasised the importance of undergraduate teaching in pain management and have developed an undergraduate curriculum. Despite this, the topic of pain, and indeed cancer pain, is currently inadequately addressed according to various studies. Additionally, the development of positive attitudes and conduct in relation to cancer pain management has also been shown to be sub-
The Challenge of Cancer Pain Assessment

optimal. Accordingly, Briggs et al. found pain education to be “fragmented, inadequately assessed and inconsistent between universities.” In practice, clinicians inexperienced in cancer pain may not have the skills to perform the relevant pain assessment, resulting in inaccurate diagnosis of pain. Anxiety about the use of regulated drugs, concerns regarding the side effects of strong analgesics and the fear of the patient developing tolerance to analgesia have also been reported as significant factors in inadequate assessment and control of cancer pain. There is, therefore, a proven need for improved education in cancer pain assessment and management at all levels of professional education to provide clinicians with the knowledge, experience and confidence to appropriately treat cancer pain.

SYSTEMATIC FACTORS: PROVISION OF SERVICES AND STANDARDISATION OF CARE

The most significant systematic barriers to achieving adequate cancer pain assessment are the healthcare setting and the lack of standardised methodology. Over the last decade, cancer care has been decontextualised with the development of purpose-built cancer centres. This has helped to streamline cancer services in secondary care. Oncology patients are, however, treated more and more often in the community for their pain. The European Prospective Investigation into Cancer and Nutrition (EPIC) study revealed that 1 in 5 patients in the community with cancer pain were not treated with analgesia while over 1 in 4 patients treated with analgesia reported pain as greater than 5 on the Numerical Rating Scale (NRS). A Marie Curie study of 1000 GPs also revealed that 6 in 10 GPs believed that the majority of their terminally ill patient’s pain was not adequately controlled. This report suggests that without additional resources and/or the development of modern technology to improve patient-doctor communication cancer pain will continue to be undertreated. Furthermore, the lack of a universally accepted methodology/tools impedes cancer pain assessment at all levels. Indeed, there are various fit-for-purpose tools but evidence of their efficacy in all groups is lacking. The development or acceptance of one method and its implementation as a standard measure would enable the development of more concrete pain assessment guidelines that could be readily introduced in all healthcare settings.

CONCLUSIONS

Cancer pain is a complex, devastating experience for patients when it is under-assessed and under-treated by healthcare professionals. The consequences extend far beyond the uncomfortable physical experience of pain, impacting all aspects of a patient’s life. In non-terminal cancer patients, it hinders recovery and can develop into chronic pain syndromes that can last a lifetime. For terminal cancer patients, the final months, weeks and days of their lives are spent in discomfort with depressed mood and impaired functioning. This is cruel to the patient and cruel to their families, who watch their loved ones suffer with a devastating illness. It is therefore imperative that we do not consider cancer pain the responsibility of the palliative care team or the oncologist, but the responsibility of every doctor, nurse and healthcare worker involved with that patient’s care. With more thoughtful consideration of the suffering of cancer patients, together we can work to eradicate a proven eradicable condition and improve the lives of many thousands of patients.

REFERENCES

1. Hanna M, Zylicz Z. Cancer pain. London: Springer; 2013.
2. Marcus DA. Epidemiology of cancer pain. Curr Pain Headache Rep. 2011;15(4):231-4.
3. Sheinfeld Gorin S, Krebs P, Badr H, Janke EA, Jim HS, Spring B, et al. Meta-analysis of psychological interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(9):539-47.
4. Nersesyan H, Slavin KV. Current approach to cancer pain management: Availability and implications of different treatment options. Ther Clin Risk Manag. 2007;3(3):381-400.
5. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514-7.
6. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-47.
7. Peacock S, Patel S. Cultural Influences on Pain. Asian Pac J Cancer Prev. 2008;9(2):6-9.
8. McCaffery M, Ferrell BR. Nurses’ knowledge of pain assessment and management: how much progress have we made? J Pain Symptom Manage. 1997;14(3):175-88.
9. Saunders C. The evolution of palliative care. J R Soc Med. 2001;94(9):430-2.
10. Ong CK, Forbes D. Embracing Cicely Saunders’ concept of total pain. BMJ. 2005;331(7516):576.
11. Brunjes GB. Spiritual pain and suffering. Asian Pac J Cancer Prev. 2010;11(Suppl 1):31-6.
12. von Gunten CF. Pathophysiology of pain in cancer. J Pediatr Hematol Oncol. 2011;33(Suppl 1):S12-8.
13. Regan JM, Peng P. Neuropathophysiology of cancer pain. Cancer Control. 2000;7(2):111-9.
14. Raphael J, Hester J, Ahmedzai S, Barrie J, Farquhar-Smith P, Williams J, et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010;11(6):872-96.
15. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. Acta Anaesthesiol Scand. 2001;45(9):1067-75.
16. Cancer pain assessment and treatment curriculum guidelines. Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology. Support Care Cancer. 1993;1(2):67-73.
17. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1965-91.
18. Weinstein SM, Romanus D, Lepisto EM, Reyes-Gibby C, Cleeand C, Greene R, et al. Documentation of pain in comprehensive cancer centers in the United States: a preliminary analysis. J Natl Compr Canc Netw. 2004;2(2):173-80.
19. Anderson KO. Assessment tools for the evaluation of pain in the oncology patient. Curr Pain Headache Rep. 2007;11(4):259-64.
20. Haefeli M, Ellering A. Pain assessment. Eur Spine J. 2006;15 Suppl 1:S17-24.
21. Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv. 2008;2(1):65-71.

22. Jacobsen R, Liubarskiene Z, Moldrup C, Chisstrup L, Sjögren P, Samsonavičienė J. Barriers to cancer pain management: a review of empirical research. Medicine (Kaunas). 2009;45(6):427-33.

23. McPherson CJ, Hadjistavropoulos T, Lobchuk MM, Kilgour KN. Cancer-related pain in older adults receiving palliative care: patient and family caregiver perspectives on the experience of pain. Pain Res Manag. 2013;18(6):293-300.

24. Graczyk M, Borkowska A, Krajnik M. Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain. Pol Arch Intern Med. 2018;128(2):89-97.

25. Paice JA, Toy C, Shott S. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage. 1998;16(1):1-9.

26. Simons LE, Elman I, Borsook D. Psychological processing in chronic pain: a neural systems approach. Neurosci Biobehav Rev. 2014;39:61-78.

27. McGuire DB, Kaiser KS, Haisfield-Wolfe ME, Iyamu F. Pain assessment in noncommunicative adult palliative care patients. Nurs Clin North Am. 2016;51(3):397-411.

28. Chen HJ, Chen YM. Pain assessment: validation of the physiologic indicators in the ventilated adult patient. Pain Manag Nurs. 2008;9(2):105-11.

29. Chen HJ, Chen YM. Pain assessment: validation of the physiologic indicators in the ventilated adult patient. Pain Manag Nurs. 2015;16(2):105-11.

30. Feldt KS. The checklist of nonverbal pain indicators (CNPI). Pain Manag Nurs. 2000;1(1):13-21.

31. Young J, Siffleet J, Nkoletti S, Shaw T. Use of a Behavioural Pain Scale to assess pain in ventilated, unconscious and/or sedated patients. Intensive Crit Care Nurs. 2006;22(1):32-9.

32. Nuseir K, Kassab M, Almomani B. Healthcare providers’ knowledge and current practice of pain assessment and management: how much progress have we made? Pain Res Manag. 2016;2016:8432973 Epub 2016 Nov 4.

33. Ali N, Thomson D. A comparison of the knowledge of chronic pain and its management between final year physiotherapy and medical students. Eur J Pain. 2009;13(1):38-50.

34. Schreiner U, Hafner A, Gologan R, Obertacke U. Effective teaching modifies medical student attitudes toward pain symptoms. Eur J Trauma Emerg Surg. 2011;37(6):655-9.

35. Murinson BB, Gordin V, Flynn S, Driver LC, Gallagher RM, Grabojs M, et al. Recommendations for a new curriculum in pain medicine for medical students: toward a career distinguished by competence and compassion. Pain Med. 2013;14(3):345-50.

36. Briggs EV, Carr EC, Whittaker MS. Survey of undergraduate pain curricula for healthcare professionals in the United Kingdom. Eur J Pain. 2011;15(8):789-95.

37. Dineen KK, DuBois JM. Between a rock and a hard place: can physicians prescribe opioids to treat pain adequately while avoiding legal sanction? Am J Law Med. 2016;42(1):7-52.

38. Wiseman T, Lucas G, Sangha A, Randolph A, Stapleton S, Pattison N, et al. Insights into the experiences of patients with cancer in London: framework analysis of free-text data from the National Cancer Patient Experience Survey 2012/2013 from the two London Integrated Cancer Systems. BMJ Open. 2015;5(10):e007792.

39. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):113-24.

40. Adam R, Murchie P. Why are we not controlling cancer pain adequately in the community? Br J Gen Pract. 2014;64(626):438-9.

41. Hjermstad MJ, Gibbins J, Haugen DF, Caraceni A, Loge JH, Kaasa S, EPCRC, European Palliative Care Research Collaborative. Pain assessment tools in palliative care: an urgent need for consensus. Palliat Med. 2008;22(8):895-903.

UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk). The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited and the new creation is licensed under identical terms.